PSMA PET-CT在前列腺癌中的病变分布及对放疗计划的影响
该回顾性研究分析了179例常规影像阴性或≤3个病灶的前列腺癌患者的PSMA PET扫描,按初诊高危、根治性前列腺切除术后和放疗后分为三组。作者推荐PSMA PET用于高危前列腺癌初始分期和生化复发再分期,并指出寡转移高比例为靶向局部治疗研究提供了机会。
要点
- PSMA PET在80%的扫描中至少检出1个病灶,即使PSA≤0.20 ng/mL时B组检出率仍达46%。
- 近三分之一扫描仅显示寡转移(A组24%、B组36%、C组31%),其中40%为孤立病灶。
核心结论
- PSMA PET可检出大量常规影像未发现的转移病灶,推荐用于高危前列腺癌初始分期及 primary therapy 后PSA复发患者的再分期。
- PSMA PET上寡转移比例高,为研究靶向局部治疗在寡转移前列腺癌中的作用提供了重要机会。
研究设计与样本
- 回顾性分析179例PSMA PET扫描,患者常规影像为阴性或≤3个病灶。
- 分为三组:A组高危前列腺癌未接受过根治性治疗(n=34),B组根治性前列腺切除术后(n=75),C组放疗后(n=70)。
- 由核医学医师基于临床经验并参考近期文献和伪影主观识别PSMA阳性病灶,绘制病灶数量和位置。
主要发现
- 共识别893个PSMA高摄取病灶,80%的扫描至少检出1个病灶。
- B组PSA≤0.20 ng/mL时检出率为46%。
- 近三分之一的研究仅显示寡转移,A、B、C组分别为24%、36%、31%,其中40%为孤立病灶。
临床怎么用
- 对高危前列腺癌初始分期可行PSMA PET以更准确评估疾病负荷。
- 对根治性治疗后PSA复发患者可行PSMA PET再分期。
- PSMA PET检出寡转移时,可考虑纳入靶向局部治疗的临床研究。
局限性
- 为回顾性研究,PSMA阳性病灶由核医学医师主观识别。
- 仅纳入常规影像阴性或≤3个病灶的患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To explore the prostate-specific membrane antigen (PSMA)-avid distribution of prostate cancer (PC) on positron emission tomography (PET), both at the time of initial diagnosis and at the time of relapse after definitive local treatment. METHODS AND MATERIALS: A total of 179 PSMA PET scans in patients with nil or ≤3 lesions on conventional imaging were retrospectively categorized into 3 subgroups: group A, high-risk PC with no prior definitive therapy (n=34); group B, prior prostatectomy (n=75); and group C, prior radiation therapy (n=70). The numbers and locations of the PSMA-avid lesions were mapped. The PSMA-positive lesions were identified subjectively by a nuclear medicine physician on the basis of clinical experience and taking into account the recent literature and artefacts. RESULTS: A total of 893 PSMA-avid lesions were identified; at least 1 lesion was detected in 80% of all scans. A high detection rate was present even at very low serum PSA levels (eg, at PSA ≤0.20 ng/mL in group B, the detection rate was 46%). Thirty-eight percent of studies revealed extrapelvic disease (41%, 31%, and 46% in groups A, B, and C, respectively). Almost one-third of all studies showed only oligometastases (24%, 36%, and 31% in groups A, B, and C, respectively). A large proportion of these (40%) were a solitary lesion. CONCLUSIONS: Prostate-specific membrane antigen PET demonstrated a large number of otherwise unknown metastatic lesions. Therefore we recommend PSMA PET for more accurate assessment of disease burden in initial staging of high-risk PC, as well as for restaging in patients with prostate-specific antigen relapse after primary therapies. Furthermore, a high proportion of oligometastases on PSMA PET provides a prime opportunity to investigate the role of targeted local therapies for oligometastatic PCs.
引用
- Gupta SK, Watson T, Denham J, et al. Prostate-Specific Membrane Antigen Positron Emission Tomography-Computed Tomography for Prostate Cancer: Distribution of Disease and Implications for Radiation Therapy Planning. Int J Radiat Oncol Biol Phys. 2017. PMID: 29280465. doi:10.1016/j.ijrobp.2017.06.2448
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。